KINETIC 2: An ongoing phase 2b, randomized, dose-response study of SAGE-324/BIIB124 for the treatment of essential tremor
Objective: KINETIC 2 (NCT05173012) is an ongoing, phase 2b, randomized, double-blind, placebo-controlled, dose-response study that aims to evaluate the efficacy, safety, and tolerability of SAGE-324/BIIB124…Cerebral Topography of [11C]-Flumazenil GABAA Receptor Expression in Parkinson’s Disease Fallers and Freezers
Objective: To examine the cerebral topography of GABAA Receptor Expression in Parkinson’s Disease (PD) Fallers and Freezers. Background: Episodic mobility disturbances, like falls and freezing…Electrophysiological correlates of neurological deficits in toxic-metabolic encephalopathy
Objective: We used transcranial magnetic stimulation (TMS) paradigms reflecting GABAA, GABAB, cholinergic and glutamatergic transmission at the motor cortex level, to investigate pathophysiology of different…A phase 2b, randomized, dose-response study of SAGE-324/BIIB124 for the treatment of essential tremor: KINETIC 2 trial in progress
Objective: The phase 2b KINETIC 2 trial is a double-blind, randomized, placebo-controlled, dose-response study designed to evaluate SAGE-324/BIIB124 (SAGE-324) for the treatment of patients with…Changes in GABAergic transmission of striatal neurons in presymptomatic Huntington’s Disease
Objective: To determine whether parameters of synaptic and extrasynaptic GABAergic inhibition of striatal projection neurons are altered in presymptomatic BACHD mice. Background: One attractive early…GABA-A Receptor Positive Allosteric Modulators: Phase 2 Proof of Concept Studies of Brexanolone Injection and SAGE-217 in Essential Tremor
Objective: To examine use of γ-aminobutyric acid (GABA) type A receptor (GABA-A-R) positive allosteric modulators (PAMs) in the treatment of essential tremor (ET) in early…Activity of Neurosteroid GABAA Positive Allosteric Modulators in Preclinical Harmaline Model for Essential Tremor
Objective: The objective of the present study was to test the activity of neurosteroid (NAS) GABAA positive allosteric modulators, including novel synthetic NAS SGE-516, at…A Case of Pregabalin induced Parkinsonism
Objective: Present a case of parkinsonism after administration of pregabalin, a rare case Background: Drug induced parkinsonism is the second common movement disorders after Parkinson’s…Ocular motor function in stiff person syndrome – Role of GABA and beyond
Objective: Delineate pathophysiology of gaze-holding function in stiff person syndrome (SPS). Background: Glutamic acid decarboxylase (GAD) catalyzes conversion of glutamate to gamma-aminobutyric acid (GABA). Anti-GAD…Intrathecal baclofen (ITB) therapy in the treatment of severe spasticity: Safety and Product Performance from a Large Multinational Multi-Center Registry
Objective: •To use real-world registry data to augment available safety data, product performance and support overall efficacy. •To utilize registry data to broaden awareness of…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.